CLOs on the Move


 
Aziyo Biologics is a fully integrated, commercially oriented regenerative medicine company. Since its founding in 2015 the Company has expanded through acquisitions and strategic partnerships, creating a high growth commercial entity. Its proprietary products are used in orthopedic, cardiovascular and other medical specialties.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.aziyo.com
  • 12510 Prosperity Drive Suite 370
    Silver Spring, MD USA 20904
  • Phone: 240.247.1170

Executives

Name Title Contact Details

Similar Companies

Calgary Scientific

Calgary Scientific is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Spotlight Therapeutics

Spotlight Therapeutics is a venture funded early-stage biotechnology company with a mission to develop a new class of therapeutics by enabling direct in vivo gene editing. Founded by Alex Marson (UCSF), Jacob Corn (UC Berkeley), and Patrick Hsu (Salk Institute) in December of 2017, Spotlight is building its core technology platform to achieve precise in vivo gene editing in targeted cell populations. With a therapeutic focus centered on oncology, our engineered nucleases edit the genes in targeted disease organs thereby inactivating or altering the gene product. We are hiring rapidly to build out our cutting-edge research and development team. This team is responsible for preclinical development ranging from protein engineering, gene editing to immuno-oncology and in vivo safety studies. Join us and work on the next generation of gene editing therapeutics in a fast-paced and exciting environment.

BC Biomedical Laboratories

BC Biomedical Laboratories Ltd. is a Surrey, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Exothera

Exothera is a CDMO delivering customized process development and GMP production services for viral vectors in Belgium

Garuda Therapeutics

Garuda Therapeutics seeks to create a world which eliminates the dependency on donor or patient cells for blood stem cell transplants. Our platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies. Like bone marrow transplants, our technology could provide potentially curative therapies for more than 70 diseases.